5.19
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NXTC Giù?
Forum
Previsione
Precedente Chiudi:
$4.92
Aprire:
$4.8
Volume 24 ore:
25,689
Relative Volume:
0.13
Capitalizzazione di mercato:
$11.13M
Reddito:
-
Utile/perdita netta:
$-58.52M
Rapporto P/E:
-2.4833
EPS:
-2.09
Flusso di cassa netto:
$-45.03M
1 W Prestazione:
+7.68%
1M Prestazione:
+1,004%
6M Prestazione:
+504.90%
1 anno Prestazione:
+224.38%
Nextcure Inc Stock (NXTC) Company Profile
Nome
Nextcure Inc
Settore
Industria
Telefono
240-399-4900
Indirizzo
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Confronta NXTC con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
NXTC
Nextcure Inc
|
5.19 | 11.13M | 0 | -58.52M | -45.03M | -2.09 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
575.92 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
327.73 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
570.25 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.76 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2022-11-04 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
2022-03-01 | Iniziato | Ladenburg Thalmann | Buy |
2021-03-05 | Aggiornamento | Truist | Hold → Buy |
2021-01-15 | Downgrade | BofA Securities | Neutral → Underperform |
2020-07-16 | Aggiornamento | The Benchmark Company | Hold → Buy |
2020-07-13 | Downgrade | ROTH Capital | Buy → Neutral |
2020-07-13 | Downgrade | SunTrust | Buy → Hold |
2020-06-01 | Downgrade | BofA/Merrill | Buy → Neutral |
2020-06-01 | Downgrade | The Benchmark Company | Buy → Hold |
2020-05-26 | Iniziato | JMP Securities | Mkt Outperform |
2020-03-24 | Iniziato | The Benchmark Company | Buy |
2020-03-02 | Iniziato | ROTH Capital | Buy |
2020-01-13 | Iniziato | SunTrust | Buy |
2019-12-05 | Iniziato | Needham | Buy |
2019-11-26 | Iniziato | BTIG Research | Buy |
2019-07-09 | Iniziato | BofA/Merrill | Buy |
2019-06-03 | Iniziato | Morgan Stanley | Overweight |
2019-06-03 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Nextcure Inc Borsa (NXTC) Ultime notizie
What analysts say about NextCure Inc. stockSuperior investment outcomes - Autocar Professional
NextCure Inc. Stock Analysis and ForecastFree Predictions - Autocar Professional
What drives NextCure Inc. stock priceExceptional return forecasts - jammulinksnews.com
Is NextCure Inc. a good long term investmentHigh-octane financial growth - Autocar Professional
What makes NextCure Inc. stock price move sharplyConsistent Growth Alert - Newser
Why NextCure Inc. stock attracts strong analyst attentionFree Access to Community - Newser
How NextCure Inc. stock performs during market volatilitySecure Your Capital Strategy - Newser
Piper Sandler lowers NextCure stock price target to $15 after reverse split By Investing.com - Investing.com South Africa
Piper Sandler lowers NextCure stock price target to $15 after reverse split - Investing.com India
NextCure initiates one-for-twelve reverse stock split on Nasdaq By Investing.com - Investing.com Nigeria
NextCure Implements Reverse Stock Split on Nasdaq - TipRanks
NextCure initiates one-for-twelve reverse stock split on Nasdaq - Investing.com
NextCure Announces One-for-Twelve Reverse Stock Split - TipRanks
NextCure announces 1-for-12 reverse stock split effective July 14 - Investing.com Nigeria
NextCure announces 1-for-12 reverse stock split effective July 14 By Investing.com - Investing.com South Africa
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
NextCure’s (NXTC) Buy Rating Reaffirmed at HC Wainwright - Defense World
Eyes on Asia: AstraZeneca, NextCure, Sagimet Biosciences - BioXconomy
Nextcure Inc: Analyzing NXTC Stock Trends - investchronicle.com
Market Recap: Next Technology Holding Inc (NXTT)’s Positive Momentum, Closing at 1.40 - DWinneX
Market Highlights: Nextcure Inc (NXTC) Ends on a Low Note at 0.50 - DWinneX
NextCure tanks as it teams up with Simcere on novel ADC - The Pharma Letter
NextCure and Simcere partner to develop SIM0505 for solid tumours - yahoo.com
NextCure partners with Simcere Zaiming on cancer drug development By Investing.com - Investing.com South Africa
NextCure Joins China-ADC Gold Rush with $745M Simcere Deal - BioSpace
NextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% Decline - Asianet Newsable
NextCure And Simcere Zaiming Partner To Develop CDH6-Targeting ADC SIM0505 For Solid Tumors - Nasdaq
NextCure signs up to $745 million deal with China's Simcere to develop cancer drug - MarketScreener
Simcere Pharmaceutical's Unit Enters Into License Agreement With Nextcure - marketscreener.com
NextCure Enters Licensing Agreement with Simcere Zaiming - TipRanks
NextCure (NXTC) Partners with Simcere Zaiming for Innovative Cancer Treatment | NXTC Stock News - GuruFocus
Nextcure Inc Azioni (NXTC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):